NDA (New Drug Application)
ANDA (Generic Application)
It is formulated by 1 pharmaceutical company such as ABBVIE. It is marketed under 1 brand name, including VENCLEXTA. Available in 3 different strengths, such as 10MG, 50MG, 100MG, and administered through 1 route including TABLET;ORAL.
Track protection status across key markets to assess launch feasibility.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
FDA approval history for this ingredient
Key expiration dates for US patents covering this ingredient
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"101841","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"88a5d4904b0846738b95","publication_number":"US9174982B2","cleaned_patent_number":"9174982","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-05-26","publication_date":"2015-11-03","legal_status":"Granted"} | US9174982B2 | 03 Nov, 2015 | Granted | 26 May, 2030 | |
| {"application_id":"101950","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"88a5d4904b0846738b95","publication_number":"US8546399B2","cleaned_patent_number":"8546399","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-06-27","publication_date":"2013-10-01","legal_status":"Granted"} | US8546399B2 Molecular Formulation | 01 Oct, 2013 | Granted | 27 Jun, 2031 | |
| {"application_id":"101969","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"60854c646c1c4b078818","publication_number":"US10730873B2","cleaned_patent_number":"10730873","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-21","publication_date":"2020-08-04","legal_status":"Granted"} | US10730873B2 Molecular | 04 Aug, 2020 | Granted | 21 Nov, 2031 | |
| {"application_id":"101995","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"60854c646c1c4b078818","publication_number":"US8722657B2","cleaned_patent_number":"8722657","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-01-29","publication_date":"2014-05-13","legal_status":"Granted"} | US8722657B2 Molecular | 13 May, 2014 | Granted | 29 Jan, 2032 | |
| {"application_id":"102005","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"21ea1f4f604b4c4c9439","publication_number":"US11369599B2","cleaned_patent_number":"11369599","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-05-23","publication_date":"2022-06-28","legal_status":"Granted"} | US11369599B2 Formulation | 28 Jun, 2022 | Granted | 23 May, 2032 | |
| {"application_id":"6888","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"5b372614902b4a65981a","publication_number":"US9539251B2","cleaned_patent_number":"9539251","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-09-06","publication_date":"2017-01-10","legal_status":"Patented case"} | US9539251B2 | 10 Jan, 2017 | Patented case | 06 Sep, 2033 | |
| {"application_id":"6892","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"5b372614902b4a65981a","publication_number":"US10993942B2","cleaned_patent_number":"10993942","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-09-06","publication_date":"2021-05-04","legal_status":"Granted"} | US10993942B2 | 04 May, 2021 | Granted | 06 Sep, 2033 | |
| {"application_id":"6890","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"5b372614902b4a65981a","publication_number":"US11110087B2","cleaned_patent_number":"11110087","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-09-06","publication_date":"2021-09-07","legal_status":"Granted"} | US11110087B2 | 07 Sep, 2021 | Granted | 06 Sep, 2033 | |
| {"application_id":"6889","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"5b372614902b4a65981a","publication_number":"US11413282B2","cleaned_patent_number":"11413282","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-09-06","publication_date":"2022-08-16","legal_status":"Granted"} | US11413282B2 | 16 Aug, 2022 | Granted | 06 Sep, 2033 | |
| {"application_id":"109200","ingredient":"VENETOCLAX","trade_name":"VENCLEXTA","family_id":"5b372614902b4a65981a","publication_number":"US11590128B2","cleaned_patent_number":"11590128","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-09-06","publication_date":"2023-02-28","legal_status":"Patented case"} | US11590128B2 | 28 Feb, 2023 | Patented case | 06 Sep, 2033 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
No suppliers found.
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.